Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 13, 2017

Primary Completion Date

May 23, 2022

Study Completion Date

April 13, 2023

Conditions
Recurrent Kaposi SarcomaSkin Kaposi Sarcoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nelfinavir Mesylate

Given PO

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

10461

Montefiore Medical Center, The Bronx

30308

Emory University/Grady Hospital, Atlanta

33136

University of Miami, Miami

43210

Ohio State University, Columbus

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine, Houston

98101

Benaroya Research Institute at Virginia Mason Medical Center, Seattle

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

02215

Beth Israel Deaconess Medical Center, Boston

Unknown

African Cancer Institute, Stellenbosch University, Cape Town

Uganda Cancer Institute, Kampala

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

University of Arkansas

OTHER

collaborator

University of California, Los Angeles

OTHER

collaborator

AIDS and Cancer Specimen Resource

OTHER

collaborator

Montefiore Medical Center

OTHER

lead

AIDS Malignancy Consortium

NETWORK

NCT03077451 - Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma | Biotech Hunter | Biotech Hunter